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We hypothesize that in vitro cultured CTL without RA lack the
ability to cause GVHD in part due to deﬁcient LPAM expres-
sion. We used an established murine GVHD model in which
B6SJL Sp/LN cells were stimulated against DBA splenocytes
with IL-2 and IL-7 with and without addition of RA (100 nm).
Day 14 comparison of CTL and CTLRA revealed comparable
CD4 and CD8 populations. CTL with and without RA showed
CD8 LPAM expression of 58% and 0.8% and CD8 CCR9 53%
and 10% respectively. In vitro cytotoxicity was comparable be-
tween CTL and CTLRA: 41% vs 51% (n  3, P  .30). Both
CTL groups had comparable in vitro migration towards SDF
(P  ns) but CTLRA had increased migration towards TECK;
17.3% vs 4.6% (n  4, P  .01). For in vivo homing, 107 labeled
cells from each CTL with (CFSE) and without RA (TRITC)
were coinjected intravenously and analysed after 16 hours.
CTLRA had increased homing to Peyers patch and MLN com-
pared to CTL without RA [homing index (CTLRA/CTL) 2.3
and 2.5 respectively]. This ﬁnding is exaggerated in the radiated
host [homing index (CTLRA/CTL) 15 for PP and 11 for
MLN]. CTL and CTLRA (5  106 cells each) were injected
intravenously with or without C57BL/6J BM into irradiated
(600 rads) B6D2F1 recipients (6 groups; radiation control,
CTL, CTLRA, BM control, CTL  BM, CTLRA  BM). Mice
were followed for clinical GVHD scores and CBC and his-
topathologic GVHD scores (liver, skin, lung, small and large
intestines) were obtained. Both CTL groups without BM rescue
developed lethal BM aplasia around day 24; however, his-
topathologic GVHD scores were similar (Table 1). CTL and
CTLRA groups with BM rescue had full hematopoietic recov-
ery, yet had similar histopathologic GVHD scores (BM control;
3.9, CTL  BM; 5, CTLRA  BM: 3.9, P  ns). Our data
demonstrate that both CTL and CTLRA cause a lethal hema-
topoietic GVH reaction which could be abrogated by parent
BM. Despite high LPAM and CCR9 expression, signiﬁcant in
vitro migration to TECK and in vivo homing to gut associated
lymphoid tissues, RA treated CTL did not cause signiﬁcant
GVHD in gut, liver or skin. This suggests that defective gut
homing alone may not be sufﬁcient to explain the attenuated
GVHD from cultured CTL (Table 1).
Table 1. Data from Day 24 Sacriﬁce
Parameter (Mean)
Radiation
Control CTL CTLRA
P
Value*
Hb (g/dL) 12.2 3.8 3.1 .0001
WBC  106/L 1000 300 300 .07
Platelets  103/L 667 200 50 200 29 500 .003
Combined GVHD
histology score
4.9 4.4 4.2 .30
*CTL or CTLRA vs radiation control group.
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EARLY TREATMENT WITH CD4CD25 REGULATORY T CELLS PRO-
VIDES PROLONGED SUPPRESSIVE EFFECTS WHICH CONTROL EVOLV-
ING BUT NOT ESTABLISHED GRAFT-VERSUS-HOST-DISEASE
Nguyen, V.H., Zeiser, R., Dasilva, D., Negrin, R.S. Stanford Univer-
sity School of Medicine, Stanford, CA.
In our previous study with Treg trafﬁcking, bioluminescence imag-
ing (BLI) indicated a persistence of signal consistent with a prolonged
survival of Treg in vivo following allogeneic bone marrow transplan-
tation. In the current study, we evaluated the duration of Treg sup-
pression and the impact of Treg on evolving and established GvHD.
Lethally irradiated Balb/c (H2d) hosts received 5  106 T-cell de-
pleted bone marrow cells from wild-type FVB mice (H2q) on day 0.
On day 2, 3 106 splenocytes, or 1 106 puriﬁed CD4/CD8 T
cells (Tcon) from luciferase transgenic mice (FVB) were infused to
induce GvHD. Treg, puriﬁed from wt-FVB mice, in a 1:1 dose ratio
with Tcon, were infused either on day 0, 2, 9, or 23 post-transplan-
tation. BLI was used to localize and quantify the proliferation of Tcon
in the absence or presence of Treg. Signal intensity, measured by
photons/second/mouse, was signiﬁcantly decreased in animals which
received Treg at day 0, 2, or 9 (P  .05). Importantly, the greatest
reduction in signal intensity occurred when Treg were given prior to
the induction of GvHD by Tcon. This reduction was associated with
a signiﬁcantly lower clinical score for GvHD. Studies in which Treg
are given up to 10 days prior to the addition of Tcon show similar
ﬁndings. At day 23, when clinical GvHD was fully established in mice
which received Tcon, the addition of Treg did not alter the increasing
BLI signal level or the clinical course such that all animals died of
GvHD (P  .38). Lymphoid reconstitution was not affected by the
addition of Treg prior to the induction of GvHD. In dose titration
studies whereby Treg are given two days prior to the induction of
GvHD, a 10-fold dose reduction in Treg was sufﬁcient to signiﬁcantly
reduce Tcon proliferation and suppress clinical GvHD. We next
assessed the duration of Treg suppressive effect by inducing GvHD
on day 7, 14, 19 with lucTcon following the infusion ofTreg on day
0 of allogeneic BMT. Treg provided protection from the Tcon
challenge at all 3 time points, leading to improved survival (P  .05).
We conclude that Treg provide prolonged protection due to their
ability to proliferate in vivo in an allogeneic setting, permitting a
signiﬁcant reduction in the number of Treg needed for adoptive
transfer to induce a clinical response. In addition, we conclude that
Treg suppress the early proliferation of Tcon, allowing them to
prevent and control evolving but not established GvHD.
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INTERLEUKIN-2 (IL-2) AND GRANULOCYTE-MACROPHAGE STIMULAT-
ING FACTOR (GM-CSF) FOR TREATMENT OF RELAPSE AFTER ALLOGE-
NEIC STEM CELL TRANSPLANT (ASCT)
Bachier, C.R., Shaughnessy, P., Wall, D., Grimley, M., LeMaistre, C.F.
Texas Transplant Institute, San Antonio, TX.
Donor lymphocyte infusion (DLI) is commonly used for relapse
after allogeneic stem cell transplant (ASCT). Immune activation
with cytokines is an alternative to DLI. We report a retrospective
analysis and ﬁrst 6 patients (pts) of a prospective study evaluating
the safety and efﬁcacy of granulocyte-macrophage stimulating fac-
tor (GM-CSF) and interleukin-2 (IL-2) administered at the time of
relapse after ASCT in pts with hematologic malignancies. Pts
received subcutaneous GM-CSF at 250 g/day on days 1-14 and
IL-2 at 1  106 units/m2/day on days 8-14. Pts were off of
immunosuppressive therapy and had no prior history of graft
versus host disease (GVHD) at the start of treatment. A total of 10
pts have received cytokine therapy with IL-2/GM-CSF for treat-
ment of relapsed AML (6), ALL (2), CML (1), MDS (1). Median
age was 45 (range 8-61). Stem cell source included: peripheral
blood  7, bone marrow  2, umbilical cord blood (UCB)  1.
Donor sources were matched-related sibling  3, matched-unre-
lated donor  7 (UCB  1). Seven pts had resistant relapse or
primary resistant disease at time of ASCT. Median time from
transplant to relapse was 4 months (range  1-14 months). Two
pts had failed DLI and 5 pts had received reinduction chemother-
apy prior to IL-2/GM-CSF. Seven pts responded to IL-2/GM-
CSF (CR  6, PR  1). Two pts remain disease free at 18 and 26
months post IL-2/GM-CSF. Six pts developed GVHD (4/6 re-
sponders). Two pts had GM-CSF discontinued due to increase in
peripheral blood blasts. No other toxicities were related to IL-2/
GM-CSF except for ﬂu-like symptoms and bone pains. In conclu-
sion, cytokine therapy with IL-2/GM-CSF is feasible and we
continue accrual to determine if this cytokine regimen is an alter-
native to DLI for relapse after ASCT.
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ELEVATED B CELL ACTIVATING FACTOR (BAFF) IN PATIENT PLASMA
AFTER ALLOGENEIC STEM CELL TRANSPLANTATION IS A POTENTIAL
BIOMARKER FOR CHRONIC GRAFT VERSUS HOST DISEASE
Sarantopoulos, S., Zorn, E., Bhuiya, N.S., Kim, H.T., Soiffer, R.J.,
Cutler, C.S., Levin, J., Antin, J.H., Ritz, J. Division of Hematologic
Malignancies, Dana Farber Cancer Institute, Boston, MA.
Previous studies have identiﬁed a highly signiﬁcant correlation
between speciﬁc antibody responses directed against recipient
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H-Y minor histocompatibility antigens and the development of
chronic graft versus host disease (cGVHD) after allogeneic
hematopoietic stem cell transplantation (HSCT). These ﬁnd-
ings suggest that donor B cells play a role in the development of
cGVHD and clinical trials utilizing anti-CD20 monoclonal an-
tibody, rituximab, have demonstrated clinical improvement in
some patients with active resistant cGVHD. B cell activating
factor, BAFF, is a member of the TNF cytokine family that
binds to one of three cell surface receptors on B cells. Activation
of these B cell receptors by antigen and BAFF results in rapid
induction of proliferation and differentiation of germinal center
B cells into either Ig-secreting cells or memory B cells. The
ﬁnding that elevated BAFF levels in patients with autoimmune
diseases are associated with disease severity and autoantibody
production has led to clinical trials using anti-BAFF monoclonal
antibody in these diseases. To test whether BAFF contributes to
the activation of B cells in patients with cGVHD, we employed
a sandwich ELISA to measure soluble BAFF in plasma from 27
patients after allogeneic HSCT. Mean BAFF levels for extensive
(n  8), limited (n  8), resolved (n  6) or no (n  5) cGVHD
groups were: 7.3 ng/ml, 5.37 ng/ml, 3.92 ng/ml and 2.02 ng/ml,
respectively. The differences between the extensive or limited
groups versus the no cGVHD group were statistically signiﬁcant
(each P  .03) suggesting that BAFF levels corresponded with
cGVHD activity. B cell subsets in peripheral blood were also
examined by ﬂow cytometry to identify circulating memory B
cells. Of four cGVHD patients analyzed thus far, individuals
with active disease and high BAFF levels also had high numbers
of CD27 memory B cells in peripheral blood compared to
patients with resolved cGVHD and low BAFF levels. Ongoing
prospective, serial assessment of BAFF levels and B cell pheno-
type in larger numbers of patients will extend these results. We
propose that BAFF may serve as a new biomarker for cGVHD,
speciﬁcally identifying patients with active disease. If further
studies identify a pathologic role for increased BAFF in
cGVHD, anti-BAFF monoclonal antibodies may provide a new
therapeutic approach for this serious complication of allogeneic
HSCT.
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TREATMENT OF MURINE ACUTE GVHD WITH THE NOVEL PRO-APOP-
TOTIC BENZODIAZEPINE BZ-423
Gatza, E.1, Clouthier, S.1, Rogers, C.1, Liu, C.2, Reddy, P.1,
Glick, G.D.1, Ferrara, J.L.M.1 1. University of Michigan Comprehen-
sive Cancer Center, Ann Arbor, MI; 2. University of Florida College of
Medicine, Gainesville, FL.
Bz-423 is a novel 1,4-benzodiazepine with both cytotoxic and
cytostatic effects on activated lymphocytes. Bz-423 has been
shown to suppress lupus in murine models by eliminating patho-
genic lymphocytes without altering normal immune function or
overt toxicities. We hypothesized that Bz-423 might enhance
the apoptotic deletion of alloreactive donor T cells and there-
fore reduce graft-versus-host disease (GVHD). We ﬁrst inves-
tigated the effect of Bz-423 on activated T cells in vitro. A 40
M concentration of Bz-423 induced apoptotic death in 	90%
of both CD4 and CD8 T lymphocytes stimulated with allo-
geneic dendritic cells (DC) or ConA in the presence of synge-
neic DC. Puriﬁed resting T cells were signiﬁcantly less suscep-
tible to Bz-423-induced apoptosis (data not shown). We next
examined the effect of Bz-423 in vivo utilizing a well-charac-
terized (Balb/c3B6) murine GVHD model. B6 recipient mice
were conditioned with 11 Gy total body irradiation and injected
with 5.0  106 bone marrow and 4-5.0  106 puriﬁed T cells
from either syngeneic (B6) or allogeneic (Balb/c) donors. In
order to model the administration of Bz-423 as a treatment
strategy rather than a prevention strategy, animals were not
treated for the ﬁrst seven days after BMT. Beginning 7 days
following BMT and continuing for the remainder of the exper-
iment, Bz-423 was administered i.p. at a dose of 60 mg/kg three
times weekly. As shown in the table below, treatment with
Bz-423 resulted in signiﬁcantly better day 60 survival (P 
.001) and reduced clinical GVHD scores (P  .02) among
allogeneic BMT recipients. Bz-423 also reduced GVH-associ-
ated immunodeﬁciency (P  .02) and decreased liver and gut
histopathology of GVHD (P  .01). Delay of the onset of
treatment to day 14 post-BMT also resulted in a signiﬁcant
survival beneﬁt (P  .03). These data demonstrate that Bz-423
can reverse acute GVHD and induce selective apoptosis of
alloreactive donor T cells in this model. Pro-apoptotic benzo-
diazepines may provide a strategy for the treatment of acute
GVHD (Table 1).
Table 1.
Syn 
Bz
Allo 
vehicle
Allo 
Bz
P
Value1
Treatment onset:
day 7
Survival (day 60) 100% (n  9) 8% (n  13) 59% (n  19) .001
GVHD clinical
score
(day 60)2
1.5  0.2 6.5  0.0 3.1  0.4 <.02
Pathology
(day 74)3
Liver 1.3  0.6 13.7  1.5 8.3  2.5 .01
Intestine 3.0  2.0 21.3  6.0 10.0  0.8 .01
Splenic
reconstitution
(day 74)3
T cells (106) 20.6  1.8 1.4  0.02 3.6  0.4 .02
B cells (106) 41.6  12.6 2.5  0.7 21.2  15.6 .02
Treatment onset:
day 14
Survival (day 60) 100% (n  3) 20% (n  5) 71% (n  6) .03
1Calculated at the 95% conﬁdence level, Allo  vehicle vs Allo 
Bz-423; 2reported as mean clinical score  SE; 3reported as mean
value  SD.
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OPPOSING EFFECTS OF ICOS ON GRAFT-VERSUS-HOST DISEASE MEDI-
ATED BY CD4 AND CD8 T CELLS
Yu, X.-Z.1, Liang, Y.1, Roza, N.I.2, Anasetti, C.1, Dong, C.2 1. H. Lee
Mofﬁtt Cancer Center, Tampa, FL; 2. M.D. Anderson Cancer Center,
Houston, TX.
Inducible costimulatory molecule (ICOS), a CD28 family mem-
ber expressed on activated CD4 and CD8 T cells, plays im-
portant roles in T cell activation and effector function. Here we
studied the role of ICOS in graft-versus-host disease (GVHD)
mediated by CD4 or CD8 T cells in allogeneic bone marrow
transplantation (BMT). In comparison of wild type (WT) and
ICOS-deﬁcient T cells, we found that recipients of ICOS/
CD4 T cells exhibited signiﬁcantly less GVHD morbidity and
mortality. ICOS/ CD4 T cells had no defect in expansion,
but expressed signiﬁcantly less FasL and produced signiﬁcantly
lower levels of IFN- and TNF-
. Thus, ICOS/ CD4 T
cells were impaired in effector functions that lead to GVHD. In
contrast, recipients of ICOS/ CD8 T cells exhibited signif-
icantly enhanced GVHD morbidity and mortality. In the absence
of ICOS signaling, either using ICOS-deﬁcient donors or ICOS-
ligand deﬁcient recipients, the levels of expansion and Tc1 cyto-
kine production of CD8 T cells were signiﬁcantly increased. The
level of expansion was inversely correlated with the level of
apoptosis, suggesting that increased ability of ICOS/ CD8 T
cells to induce GVHD was resulted from the enhanced survival and
expansion of those cells. Our ﬁndings indicate that ICOS has
paradoxical effects on the regulation of alloreactive CD4 and
CD8 T cells in GVHD.
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HIGHER CLEARANCE RATES OF MYCOPHENOLATE MOFETIL (MMF) IN
PEDIATRIC ALLOGENEIC STEM CELL TRANSPLANT (AlloSCT) RECIPI-
ENTS
Militano, O.1, Roache, K.2, Shaw, L.M.3, Figurski, M.3, Satwani, P.2,
Ayello, J.2, Roman, E.2, Del Toro, G.2, Bradley, B.2, George, D.2,
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